Results from a large target trial emulation study reflect benefits in older patients up to age 80.
Medscape Medical News
Source link : https://www.medscape.com/viewarticle/sglt2-inhibitor-top-dpp-4-inhibitor-survival-diabetic-kidney-2026a100058w?src=rss
Author :
Publish date : 2026-02-19 11:04:00
Copyright for syndicated content belongs to the linked Source.